{
    "organizations": [],
    "uuid": "5a54da8338cdf239829a05f5627a5e27c045f346",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-approves-pdufa-fee-waiver-for/brief-fda-approves-pdufa-fee-waiver-for-gimoti-new-drug-application-idUSASB0C8Q9",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Approves PDUFA Fee Waiver For Gimoti New Drug Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Evoke Pharma Inc:\n* FDA APPROVES PDUFA FEE WAIVER FOR GIMOTIâ„¢ NEW DRUG APPLICATION\n* FDA GRANTED ITS REQUEST FOR SMALL BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR ITS TREATMENT GIMOTI\n* COMPANY REMAINS ON TRACK TO FILE GIMOTI NDA NEXT QUARTER * LOOK FORWARD TO POTENTIAL U.S. PRODUCT LAUNCH IN 2019 OF GIMOTI\n* AS CO REVIEWS 2018 BUDGET, ABLE TO EXTEND CASH RUNWAY INTO OCTOBER 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T20:41:00.000+02:00",
    "crawled": "2018-03-06T22:22:21.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "evoke",
        "pharma",
        "inc",
        "fda",
        "approves",
        "pdufa",
        "fee",
        "waiver",
        "new",
        "drug",
        "application",
        "fda",
        "granted",
        "request",
        "small",
        "business",
        "waiver",
        "pdufa",
        "fee",
        "million",
        "treatment",
        "gimoti",
        "company",
        "remains",
        "track",
        "file",
        "gimoti",
        "nda",
        "next",
        "quarter",
        "look",
        "forward",
        "potential",
        "product",
        "launch",
        "gimoti",
        "co",
        "review",
        "budget",
        "able",
        "extend",
        "cash",
        "runway",
        "october",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}